Department of Medicine Grand Rounds: The Omicron Variant and the New Antivirals: How Much Will These Change the Pandemic in 2022?
-
Annie Luetkemeyer, MD is a professor of medicine in the Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General Hospital at University of California, San Francisco. She leads clinical trials examining novel therapeutics and preventative strategies for COVID-19, including antivirals, anti-inflammatories and vaccinations. Dr. Luetkemeyer co-chairs the UCSF Interventional COVID Clinical Trials Committee. She is the site principal investigator for the UCSF Coronavirus Prevention Network (CoVPN) and the UCSF AIDS Clinical Trials Group (ACTG).
John P. Moore, PhD is a tenured Professor of Microbiology and Immunology at Weill Cornell Medical College in New York. He received his B.A., M.A., M.Phil. and Ph.D. degrees from Cambridge University, UK. He moved to the USA in 1992, joining the Medical College in 2000.
Moore was an Elizabeth Glaser Scientist of the Pediatric AIDS Foundation and held a Merit Award from NIAID. He is an Editorial Board member for several journals, and has served on multiple study sections and review committees for NIH and charities.
Moore’s research for many years has focussed on understanding how HIV-1 enters cells and how to inhibit virus entry with specific drug candidates and antibodies. He presently directs intra- and multi-laboratory projects involving the design of HIV-1 envelope glycoprotein trimers for neutralizing antibody induction and structural studies. Some of these immunogens are now in Phase 1 clinical trials. Since March 2020, a significant proportion of Moore’s time has been spent on virology and vaccine topics related to SARS-CoV-2 and the COVID-19 pandemic, particularly to provide guidance to reporters and members of the public.
Add to Calendar2021-12-02 12:00:002021-12-02 13:00:00Department of Medicine Grand Rounds: The Omicron Variant and the New Antivirals: How Much Will These Change the Pandemic in 2022?
Annie Luetkemeyer, MD is a professor of medicine in the Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General Hospital at University of California, San Francisco. She leads clinical trials examining novel therapeutics and preventative strategies for COVID-19, including antivirals, anti-inflammatories and vaccinations. Dr. Luetkemeyer co-chairs the UCSF Interventional COVID Clinical Trials Committee. She is the site principal investigator for the UCSF Coronavirus Prevention Network (CoVPN) and the UCSF AIDS Clinical Trials Group (ACTG).
John P. Moore, PhD is a tenured Professor of Microbiology and Immunology at Weill Cornell Medical College in New York. He received his B.A., M.A., M.Phil. and Ph.D. degrees from Cambridge University, UK. He moved to the USA in 1992, joining the Medical College in 2000.
Moore was an Elizabeth Glaser Scientist of the Pediatric AIDS Foundation and held a Merit Award from NIAID. He is an Editorial Board member for several journals, and has served on multiple study sections and review committees for NIH and charities.
Moore’s research for many years has focussed on understanding how HIV-1 enters cells and how to inhibit virus entry with specific drug candidates and antibodies. He presently directs intra- and multi-laboratory projects involving the design of HIV-1 envelope glycoprotein trimers for neutralizing antibody induction and structural studies. Some of these immunogens are now in Phase 1 clinical trials. Since March 2020, a significant proportion of Moore’s time has been spent on virology and vaccine topics related to SARS-CoV-2 and the COVID-19 pandemic, particularly to provide guidance to reporters and members of the public.
Please click the link below to join the webinar: https://ucsf.zoom.us/j/92507991004?pwd=UGg0NU0xS2R0Q1RtREpSK2UzUyt2dz09
Webinar ID: 925 0799 1004
Passcode: 500062
[email protected]Department of MedicineAmerica/Los_Angelespublic
